Cronos Group (CRON) vs Pacira BioSciences (PCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cronos Group (CRON) has outperformed Pacira BioSciences (PCRX) over the past year, gaining 23.7% versus a gain of 6.7%. Over five years, CRON leads with a -40.9% price change compared with -52.6% for PCRX. Pacira BioSciences is the larger company by market cap ($1.45 billion vs $1.18 billion), about 1.2 times the size.
On valuation, Cronos Group trades at a lower trailing P/E (16.9x vs 103.9x for Pacira BioSciences).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRON | PCRX |
|---|---|---|
| Share price | $3.21 | $36.38 |
| Market cap | $1.18B | $1.45B |
| 1-day change | -0.93% | +44.35% |
| YTD return | +23.19% | -2.63% |
| 1-year return | +23.66% | +6.69% |
| 5-year return | -40.88% | -52.63% |
| P/E ratio (TTM) | 16.89 | 103.93 |
| Forward P/E | — | 10.52 |
| EPS (TTM) | $0.19 | $0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.61 | $36.39 |
| 52-week low | $2.28 | $18.80 |
| Distance from 52-week high | -11.03% | -0.04% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | -23.36% | -17.22% |
| Average volume | 1.13M | 588.87K |
| Shares outstanding | 368.41M | 39.86M |
| Employees | 610 | 825 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRON has outperformed PCRX by 17.0 percentage points over the past year.
- Pacira BioSciences trades at a higher earnings multiple (103.9x vs 16.9x trailing P/E).
About Cronos Group
CRON stock →Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names.
Health Care · Medicinal Chemicals and Botanical Products · 610 employees
About Pacira BioSciences
PCRX stock →Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 825 employees
CRON vs PCRX FAQ
Which is bigger, Cronos Group or Pacira BioSciences?
Pacira BioSciences (PCRX) is larger, with a market capitalization of $1.45B compared with $1.18B for Cronos Group (CRON).
Which stock has performed better over the past year, CRON or PCRX?
CRON returned +23.66% over the past 12 months, compared with +6.69% for PCRX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CRON or PCRX?
CRON has the lower trailing P/E at 16.9, versus 103.9 for PCRX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Cronos Group and Pacira BioSciences in the same industry?
Both are in the Health Care sector, but in different industries: Medicinal Chemicals and Botanical Products for Cronos Group and Biotechnology: Pharmaceutical Preparations for Pacira BioSciences.